Search fresh public links, source activity, and post angles for Biocon.
Fresh curated links around Biocon are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Biocon: Nuvama said Q4FY26 growth moderated as Biocon upgraded facilities to scale up capacity in response to anticipated demand in the US and Europe.
Synopsis: Biocon Limited received Health Canada approval for Bosayaâ„¢ and Vevzuoâ„¢, denosumab biosimilars for osteoporosis and cancer-related bone conditions, expanding global re...
Synopsis: Biocon Limited received Health Canada approval for Bosayaâ„¢ and Vevzuoâ„¢, denosumab biosimilars for osteoporosis and cancer-related bone conditions, expanding global re...
नई दिल्ली: भारत की मशहूर Biotech Entrepreneur Kiran Mazumdar-Shaw ने अपनी कंपनी के भविष्य को लेकर बड़ा कदम उठाया है। उन्होंने अपनी भतीजी Claire Mazumdar को अपना उत्तराधिकारी चुना ह...
Claire Mazumdar, 37 years of age, currently heads Bicara Therapeutics as its founder and CEO. The firm, which was incubated by Biocon and later listed on NASDAQ, went public in 202...
On April 7, 2026, Biocon announced the U.S. commercial launch of Bosaya™ / Aukelso™ (denosumab-kyqq), biosimilars of Amgen’s Prolia® / Xgeva® (denosumab)....By: Venable L...
On April 2, 2026, Biocon filed a petition for post-grant review (“PGR”) challenging Regeneron’s U.S. Patent No. 12,168,036 (“the ’036 patent”), which is directed to methods for tre...
Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...
The decline was largely attributed to exceptional costs, including employee-related expenses, and the ongoing impact of destocking by a key biologics client linked to Librela.
The decline was largely attributed to exceptional costs, including employee-related expenses, and the ongoing impact of destocking by a key biologics client linked to Librela.
Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...
Synopsis: Indegene Limited is revolutionising life sciences by integrating generative AI into its domain-led operating model. By achieving record FY26 revenues of Rs.3,510 crore an...
Revenue rises 3% to Rs 3,739 crore; margins contract to 25% even as Q4 shows sequential recovery
Banyan BioInnovations is debuting with more than $100 million aimed at developing NewCos around promising clinical assets, plus a partnership with global contract research organiza...
Oral semaglutide, a glucagon-Like Peptide-1 receptor agonist (GLP-1 RA), is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes...
Overseas sales outpace domestic growth; company scales injectables, biosimilars, expands in Europe, Canada
BridgeBio Anonymous (not verified) Mon, 05/11/2026 - 11:23 field_thread_url https://cafepharma.com/boards/threads/bridgebio.698762/ boar...
Worth up to $300 million, the buyout is Lilly’s latest of an ADC maker and adds technology for making “dual-payload” therapies.
Other pharma stocks, including Wockhardt Ltd, Lupin Ltd, Divi's Laboratories Ltd, Zydus Lifesciences Ltd, Torrent Pharmaceuticals Ltd, JB Chemicals & Pharmaceuticals Ltd, Manki...
Lilly's FDA approval of Foundayo puts it in direct competition with Novo Nordisk's oral Wegovy. Back home, Indian companies are lining up their own GLP-1 bets from generics to nove...
A WA biotech duo, ProGenis and Syngenis Laboratories, is developing RNA-based therapies at the next frontier in diabetes medicine, while building Australia’s first RNA facility.
This is the first time such huge investments are being made. The Indian pharmaceutical industry has grown from small companies into multinational corporations. Out of the top 20 gl...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.